

HLA-DQB1 RABBIT PAB

Cat.#: S218851

Product Name: Anti-HLA-DQB1 Rabbit Polyclonal Antibody

Synonyms: IDDM1; CELIAC1; HLA-DQB

UNIPROT ID: P01920 (Gene Accession - BC012106)

Background: HLA-DQB1 belongs to the HLA class II beta chain paralogs. This class II molecule is a heterodimer consisting of an alpha (DQA) and a beta chain (DQB), both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The beta chain is approximately 26-28 kDa and it contains six exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DQ molecule both the alpha chain and the beta chain contain the polymorphisms specifying the peptide binding specificities, resulting in up to four different molecules. Typing for these polymorphisms is routinely done for bone marrow transplantation. Alternative splicing results in multiple transcript variants.

Immunogen: Fusion protein of human HLA-DQB1

Applications: ELISA, IHC

Recommended Dilutions: IHC: 25-100; ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Immunology

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human prostate cancer tissue using 218851(HLA-DQB1 Antibody) at a dilution of 1/35(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with the fusion protein and then with 218851(Anti-HLA-DQB1 Antibody) at dilution 1/35.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
